At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MEDP Medpace
Pre-Mkt 10-29 09:19:27 EDT
692.68
+18.89
+2.80%
盘前693.40
+0.72+0.10%
08:06 EDT
High693.97Low671.56Vol301.52K
Open671.56D1 Closing673.79Amplitude3.33%
Mkt Cap19.33BTradable Cap15.75BTotal Shares27.91M
T/O207.45MT/O Rate1.33%Tradable Shares22.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Medpace Executive VP of Operations Susan E. Burwig Reports Sale of $13.54 Million in Common Shares
Reuters  ·  04:24
Medpace Executive VP of Operations Susan E. Burwig Reports Sale of $13.54 Million in Common Shares
Medpace Holdings Price Target Raised to $670.00/Share from $600.00 by BMO Capital
Dow Jones  ·  10-27 01:35
Medpace Holdings Price Target Raised to $670.00/Share from $600.00 by BMO Capital
Medpace Holdings Inc. Signals Strong Growth in Earnings Call
TIPRANKS  ·  10-24
Medpace Holdings Inc. Signals Strong Growth in Earnings Call
Medpace Holdings is Maintained at Neutral by UBS
Dow Jones  ·  10-24
Medpace Holdings is Maintained at Neutral by UBS
Medpace's Bookings, Pre-Backlog Trends Support Growth Outlook, UBS Says
MT Newswires Live  ·  10-24
Medpace's Bookings, Pre-Backlog Trends Support Growth Outlook, UBS Says
UBS Adjusts Price Target on Medpace to $700 From $673, Maintains Neutral Rating
MT Newswires Live  ·  10-23
UBS Adjusts Price Target on Medpace to $700 From $673, Maintains Neutral Rating
RBC Capital Keeps Their Buy Rating on Medpace Holdings (MEDP)
TIPRANKS  ·  10-23
RBC Capital Keeps Their Buy Rating on Medpace Holdings (MEDP)
Medpace price target raised to $730 from $700 at Mizuho
TIPRANKS  ·  10-23
Medpace price target raised to $730 from $700 at Mizuho
Medpace price target raised to $699 from $638 at Baird
TIPRANKS  ·  10-23
Medpace price target raised to $699 from $638 at Baird
Medpace Holdings, Inc. : Jefferies Raises Target Price to $600 from $560
THOMSON REUTERS  ·  10-23
Medpace Holdings, Inc. : Jefferies Raises Target Price to $600 from $560
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perrigo Company (PRGO), Thermo Fisher (TMO) and Medpace Holdings (MEDP)
TIPRANKS  ·  10-22
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perrigo Company (PRGO), Thermo Fisher (TMO) and Medpace Holdings (MEDP)
Deutsche Bank Adjusts Medpace Price Target to $650 From $535, Maintains Hold Rating
MT Newswires Live  ·  10-22
Deutsche Bank Adjusts Medpace Price Target to $650 From $535, Maintains Hold Rating
Medpace Holdings, Inc. : Deutsche Bank Raises Target Price to $650 from $535
THOMSON REUTERS  ·  10-22
Medpace Holdings, Inc. : Deutsche Bank Raises Target Price to $650 from $535
Barclays Sticks to Its Hold Rating for Medpace Holdings (MEDP)
TIPRANKS  ·  10-22
Barclays Sticks to Its Hold Rating for Medpace Holdings (MEDP)
France's Sartorius Stedim Biotech 9-Month Revenue up 6.5%
Reuters  ·  10-22
France's Sartorius Stedim Biotech 9-Month Revenue up 6.5%
Medpace Holdings, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Reuters  ·  10-22
Medpace Holdings, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Medpace Holdings Gets $1B Buyback Authorization, Reports Higher 3Q Profit
Dow Jones  ·  10-22
Medpace Holdings Gets $1B Buyback Authorization, Reports Higher 3Q Profit
GUIDANCE: (MEDP) Medpace Expects Full Year 2026 Revenue Range $2.84B - $2.86B, vs. FactSet Est of $2.85B
MT Newswires Live  ·  10-22
GUIDANCE: (MEDP) Medpace Expects Full Year 2026 Revenue Range $2.84B - $2.86B, vs. FactSet Est of $2.85B
Earnings Flash (MEDP) Medpace Posts Q3 EPS $4.84, vs. FactSet Est of $4.44
MT Newswires Live  ·  10-22
Earnings Flash (MEDP) Medpace Posts Q3 EPS $4.84, vs. FactSet Est of $4.44
Medpace Q3 Revenue Rises 8.5%, Slightly Beats Analyst Estimates
Reuters  ·  10-22
Medpace Q3 Revenue Rises 8.5%, Slightly Beats Analyst Estimates

Introduction

Company Name.
Medpace
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Issue price:
--